A broad-spectrum macrocyclic peptide inhibitor of the SARS-CoV-2 spike protein
Thijssen, V.; Hurdiss, D. L.; Debski-Antoniak, O. J.; Spence, M. A.; Franck, C.; Norman, A.; Aggarwal, A.; Mokiem, N. J.; van Dongen, D. A. A.; Vermeir, S. W.; Liu, M.; Chatziandreou, M.; Donselaar, T.; Du, W.; Drulyte, I.; Bosch, B. J.; Snijder, J.; Turville, S. G.; Payne, R. J.; Jackson, C. J.; van Kuppeveld, F. J. M.; Jongkees, S. A. K.
Show abstract
The ongoing COVID-19 pandemic has had great societal and health consequences. Despite the availability of vaccines, infection rates remain high due to immune evasive Omicron sublineages. Broad-spectrum antivirals are needed to safeguard against emerging variants and future pandemics. We used mRNA display under a reprogrammed genetic code to find a spike-targeting macrocyclic peptide that inhibits SARS-CoV-2 Wuhan strain infection and pseudoviruses containing spike proteins of SARS-CoV-2 variants or related sarbecoviruses. Structural and bioinformatic analyses reveal a conserved binding pocket between the receptor binding domain, N-terminal domain and S2 region, distal to the ACE2 receptor-interaction site. Our data reveal a hitherto unexplored site of vulnerability in sarbecoviruses that peptides and potentially other drug-like molecules can target. Significance statementThis study reports on the discovery of a macrocyclic peptide that is able to inhibit SARS-CoV-2 infection by exploiting a new vulnerable site in the spike glycoprotein. This region is highly conserved across SARS-CoV-2 variants and the subgenus sarbecovirus. Due to the inaccessability and mutational contraint of this site, it is anticipated to be resistant to the development of resistance through antibody selective pressure. In addition to the discovery of a new molecule for development of potential new peptide or biomolecule therapeutics, the discovery of this broadly active conserved site can also stimulate a new direction of drug development, which together may prevent future outbreaks of related viruses.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Identification of Covalent Cyclic Peptide Inhibitors Targeting Protein-Protein Interactions Using Phage Display 95%
- Using a function-first "scout fragment"-based approach to develop allosteric covalent inhibitors of conformationally dynamic helicase mechanoenzymes 95%
- Engineering protease-resistant peptides to inhibit human parainfluenza viral respiratory infection 95%
Similar papers in this journal
- Peptide-antibody Fusions Engineered by Phage Display Exhibit Ultrapotent and Broad Neutralization of SARS-CoV-2 Variants 95%
- Designer small molecule control system based on Minocycline induced disruption of protein-protein interaction. 95%
- Controlled protein activities with viral proteases, antiviral peptides, and antiviral drugs 95%
Similar papers in this journal
- A Recurring Chemogenetic Switch for Chimeric Antigen Receptor T Cells 94%
- Development of DuoMYC: a synthetic cell penetrant miniprotein that efficiently inhibits the oncogenic transcription factor MYC 93%
- Machine learning-augmented molecular dynamics simulations (MD) reveal insights into the disconnect between affinity and activation of ZTPriboswitch ligands 93%
Similar papers in this journal
- Structural insights into VRC01-class bnAb precursors with diverse light chains elicited in the IAVI G001 human vaccine trial 96%
- An influenza A hemagglutinin small-molecule fusion inhibitor identified by a new high-throughput fluorescence polarization screen. 96%
- Cyclic peptides can engage a single binding pocket through multiple, entirely divergent modes 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.